Dan Teleman

Mr. Teleman joined Atox Bio in 2010. Prior to joining Atox Bio, Mr. Teleman was the co-founder and CEO of PainReform, a specialty pharmaceutical company focused on pain therapeutics. Before founding PainReform in 2007, Mr. Teleman was a senior Business Development officer at Pharmos, a company focused on the R&D of novel CB2 receptor agonists for the treatment of neuropathic and inflammatory pain. Prior to Pharmos, Mr. Teleman held marketing and sales positions at Amgen, working on Enbrel. Dan served as an officer in an Israel Defense Forces R&D unit, holds an MBA from Duke University-Fuqua School of Business and an MSc in Biotechnology from Ben Gurion University.

Dan Teleman is the CEO at Atox Bio, based in Asia. With a background in Biotechnology, Dan Teleman has a rich history of leadership and innovation. Dan Teleman studied MSc Biochemical Engineering @ Ben-Gurion University of the Negev. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.